Structure-guided rescaffolding of selective antagonists of BCL-XL
Publication Year 2014-06-12,Volume 5,Issue #6,Page 662-7
Journal Title
ACS Med Chem Lett
Publication Type
Journal Article
Because of the promise of BCL-2 antagonists in combating chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), interest in additional selective antagonists of antiapoptotic proteins has grown. Beginning with a series of selective, potent BCL-XL antagonists containing an undesirable hydrazone functionality, in silico design and X-ray crystallography were utilized to develop alternative scaffolds that retained the selectivity and potency of the starting compounds.
WEHI Research Division(s)
Chemical Biology; Structural Biology
NHMRC Grants
Terms of Use/Rights Notice
Refer to copyright notice on published article.

Creation Date: 2014-06-23 08:42:21
Last Modified: 2015-03-26 02:49:24
An error has occurred. This application may no longer respond until reloaded. Reload 🗙